On November 2, 2015, drugmaker Alexion Pharmaceuticals Inc. announced in a quarterly securities filing that it recently received a request from the U.S. Department of Justice (DOJ) for the voluntary production of documents related to the company’s compliance with the FCPA. Alexion, a Connecticut-based biopharmaceutical company that focuses on the development of treatments for rare diseases, disclosed in May 2015 that it had received a subpoena from the Securities and Exchange Commission (SEC) related to an investigation of the company’s grant application activities and potential violations of the FCPA. While the SEC’s subpoena also requested information related to Alexion’s June 2014 voluntary recall of its drug Soliris, the company’s best known drug, the DOJ’s request was limited to compliance with the FCPA.
Alexion said that it is fully cooperating with the investigations and that it “does not currently believe a loss related to these matters is probable or that the potential magnitude of such loss or range of loss, if any, can be reasonably estimated.”
To learn more, read coverage from The Wall Street Journal.